Does IPILIMUMAB Cause Malignant neoplasm progression? 3,296 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 3,296 reports of Malignant neoplasm progression have been filed in association with IPILIMUMAB (YERVOY). This represents 9.0% of all adverse event reports for IPILIMUMAB.
3,296
Reports of Malignant neoplasm progression with IPILIMUMAB
9.0%
of all IPILIMUMAB reports
1,570
Deaths
1,538
Hospitalizations
How Dangerous Is Malignant neoplasm progression From IPILIMUMAB?
Of the 3,296 reports, 1,570 (47.6%) resulted in death, 1,538 (46.7%) required hospitalization, and 280 (8.5%) were considered life-threatening.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for IPILIMUMAB. However, 3,296 reports have been filed with the FAERS database.
What Other Side Effects Does IPILIMUMAB Cause?
Death (3,710)
Diarrhoea (2,557)
Off label use (2,097)
Colitis (1,988)
Pyrexia (1,796)
Rash (1,556)
Fatigue (1,447)
Intentional product use issue (1,329)
Nausea (1,169)
Decreased appetite (990)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
FULVESTRANT (3,221)
LENVATINIB (2,929)
OSIMERTINIB (2,920)
Which IPILIMUMAB Alternatives Have Lower Malignant neoplasm progression Risk?
IPILIMUMAB vs IPRAGLIFLOZIN L-PROLINE
IPILIMUMAB vs IPRATROPIUM
IPILIMUMAB vs IPRATROPIUM\IPRATROPIUM ANHYDROUS
IPILIMUMAB vs IPTACOPAN
IPILIMUMAB vs IRBESARTAN